These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pulmonary infiltrates and skin pigmentation associated with sulfasalazine. Gabazza EC; Taguchi O; Yamakami T; Machishi M; Ibata H; Suzuki S; Matsumoto K; Kitagawa T; Yamamoto J Am J Gastroenterol; 1992 Nov; 87(11):1654-7. PubMed ID: 1359782 [TBL] [Abstract][Full Text] [Related]
6. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. Korelitz BI; Present DH; Rubin PH; Fochios SE J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature. Yamakado S; Yoshida Y; Yamada T; Kishida T; Kobayashi M; Nomura T Intern Med; 1992 Jan; 31(1):108-13. PubMed ID: 1348965 [TBL] [Abstract][Full Text] [Related]
8. [Pathological changes in lungs and liver after therapy of ulcerative colitis]. Matek W; Rösch W; Becker V Fortschr Med; 1980 Apr; 98(13):491-6. PubMed ID: 6102956 [No Abstract] [Full Text] [Related]
10. Interstitial pneumonia due to sulfasalazine. Sigvaldason A; Sörenson S Eur J Respir Dis; 1983 Apr; 64(3):229-33. PubMed ID: 6132833 [TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. Tolia V Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658 [TBL] [Abstract][Full Text] [Related]
13. Sulfasalazine pneumonitis. Yaffe BH; Korelitz BI Am J Gastroenterol; 1983 Aug; 78(8):493-4. PubMed ID: 6136183 [TBL] [Abstract][Full Text] [Related]
14. Adverse reactions to infliximab and the outcome of desensitization. Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777 [TBL] [Abstract][Full Text] [Related]
15. Rapid iron desensitization after generalized urticaria and facial angioedema. Rodríguez-Jiménez B; Domínguez-Ortega J; Nuñez-Acevedo B; Cava-Sumner B; Kindelan-Recarte C; Montojo-Guillén C J Investig Allergol Clin Immunol; 2014; 24(1):69-71. PubMed ID: 24765889 [No Abstract] [Full Text] [Related]
16. Sulphasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. Leino R; Liippo K; Ekfors T J Intern Med; 1991 Jun; 229(6):553-6. PubMed ID: 1675246 [TBL] [Abstract][Full Text] [Related]
17. Desensitization of patients with inflammatory bowel disease to sulfasalazine. Taffet SL; Das KM Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032 [TBL] [Abstract][Full Text] [Related]
18. [Tubular-interstitial nephritis and fibrosing alveolitis induced by sulfasalazine in ulcerative colitis]. Avdeev VG; Fomin VV; Popova EN; Iurkevich LIu; Osipenko VI; Sokolina IA; Popova IA Ter Arkh; 2006; 78(1):77-9. PubMed ID: 16512452 [No Abstract] [Full Text] [Related]
19. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H; Munakata A; Yoshida Y J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870 [TBL] [Abstract][Full Text] [Related]
20. Current status of drug therapy for inflammatory bowel disease. Peppercorn MA Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]